Changes in Results of Gallium-67-Citrate Scanning after Interferon Therapy for Chronic Hepatitis C

Susumu Shiomi, Tetsuo Kuroki, Tadashi Yokogawa, Tadashi Takeda, Shuhei Nishiguchi, Shinya Nakajima, Takashi Tanaka, Terue Okamura and Hironobu Ochi

Third Department of Internal Medicine, Department of Public Health and Division of Nuclear Medicine, Osaka City University Medical School, Osaka, Japan

Gallium-67 scanning is useful for early diagnosis and grading of interstitial lung disease. In a study of the side effects of interferon (IFN) on the lungs of patients with chronic hepatitis C, we performed 67Ga scanning before and after IFN therapy. Methods: 21 patients with chronic hepatitis 2A (CAH-2A), 25 with chronic aggressive hepatitis 2B (CAH-2B) and 12 with cirrhosis. All had underlying hepatitis C viral infection. Of those patients, 20 were examined again within 1 mo after IFN therapy. Patients received an intravenous injection of 340 MBq 67Ga-citrate and were imaged 2 hr later. ROIs were established for anterior views of the lungs (Lu), liver (Ll) and soft tissue of the upper arm as background (B). The counts per unit size of each region of interest were used in calculation of the ratios Lu/B and Ll/B. Results: The medians of Lu/B were 2.46 in CAH-2A, 2.50 in CAH-2B and 2.47 in cirrhosis. These differences were not statistically significant. The medians of Ll/B were 6.42 in CAH-2A, 5.11 in CAH-2B and 4.03 in cirrhosis. The differences between the median Ll/B of cirrhotic patients and the medians for patients with CAH-2A and CAH-2B were significant. After therapy, Ll/B was higher than before in 16 of the 20 patients and lower in the four other patients; the overall rise was significant (Wilcoxon rank-sum test). Ll/B was higher than before in 11 of the 20 patients and lower in the nine other patients. Conclusion: IFN caused uptake of the radionuclide to increase in most patients. This method showed changes in the accumulation of 67Ga-citrate that could have been missed if the results had been inspected by eye. IFN can cause interstitial lung disease, but unlike other drugs with this side effect, the onset seems to be gradual enough to be detected quantitatively by 67Ga scanning.

Key Words: gallium-67-citrate; interferon-alpha; hepatitis C; interstitial lung disease

J Nucl Med 1997; 38:216-219

Chronic hepatitis B is often treated with interferon (IFN) (1), which can cause such side effects as fever of 38°C or more, influenza-like symptoms, thrombocytopenia, leukopenia, proteinuria and alopecia (2). Administration is long term when infection is with the hepatitis C virus (3), and further side effects may appear. The most troublesome are autoimmune thyroid disease (4–6), autoimmune hepatitis (7,8), worsening of diabetes mellitus (9,10), psychiatric disorders (11,12) and interstitial lung disease (13–17). Interstitial lung disease, in particular, has a poor prognosis, and early diagnosis and treatment are needed. Gallium-67 scanning is generally useful for the early diagnosis of interstitial lung disease (18). It might be improved by being made quantitative rather than qualitative. To identify the effect of IFN on the lungs, we performed 67Ga scanning in patients with chronic hepatitis C before and after IFN therapy, with quantitative results used to monitor responses and, in some cases, to exclude patients from IFN therapy when uptake in the first scanning was unusually high.

MATERIALS AND METHODS

Patients

Sixty-six patients with underlying hepatitis C viral infection underwent at least one scanning (before IFN therapy). Thirty-six patients were men and 30 were women; the mean age was 50 yr (range 21–67 yr). Chronic hepatitis C was diagnosed by the detection of antibodies to hepatitis C virus. Diagnoses of the liver condition were based on histological examination of liver specimens obtained by laparoscopy or needle biopsy done under ultrasonic guidance between April 1993 and August 1995. Results of the histological examination, which was done by internationally established criteria (19), showed that there were eight patients with chronic persistent hepatitis (CPH), 21 patients with chronic aggressive hepatitis 2A (CAH-2A) with moderate piecemeal necrosis and inflammation (20), 25 patients with chronic aggressive hepatitis 2B in which these two signs were severe (CAH-2B) and 12 patients with cirrhosis of the liver. The 67Ga scanning before therapy was done within 1 wk of liver biopsy. All patients were asked and 20 patients agreed to return as outpatients to be examined a second time within 1 mo of the end of IFN therapy. We classified all patients into three categories according to their changes in alanine aminotransferase (ALT) activity with IFN therapy. Responders were those in whom ALT activity at the end of IFN therapy was normal. Partial responders were those in whom ALT activity had decreased but not to the normal level by the end of IFN therapy. Nonresponders were those in whom ALT activity had not decreased by the end of IFN therapy. The clinical background of patients scanned twice and their responses to IFN therapy are shown in Table 1.
Scintigraphy

Patients received an intravenous injection of 340 MBq of $^{67}$Ga-citrate, and both anterior and posterior views of the thorax were taken 72 hr later with a gamma camera (Sopha Medical DSX, Paris, France) fitted with a medium-energy collimator. The pulse-height analyzer was set for 93-, 184- and 296-keV photopeaks. Anterior views, in which one view comprised 800,000 counts, were analyzed.

The collected data were processed by computer and shown on a color display. ROIs were established for the anterior views of the lungs (Lu), liver (Li) and soft tissue of the upper arm as background (B). The counts per unit size of each ROI were used in calculations of the ratio of the lung count to the background count (Lu/B) and the ratio of the liver count to the background count (Li/B).

Statistical analysis

Results are expressed as medians with tenth and 90th percentiles. The significance of differences between medians was evaluated by the Mann-Whitney U-test (two-tailed). The changes in Lu/B and Li/B after IFN therapy were evaluated with the Wilcoxon rank-sum test (two-tailed). For both tests, differences with probability values of less than 0.05 were considered to be statistically significant.

RESULTS

Lung and Liver Uptake of Gallium-67-Citrate in Chronic Liver Diseases

The medians (tenth and 90th percentiles) of Lu/B were 2.46 (2.12, 2.93) in CPH, 2.56 (2.15, 3.39) in CAH-2A, 2.50 (2.12, 3.69) in CAH-2B and 2.47 (2.00, 2.74) in cirrhosis of the liver.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Diagnosis</th>
<th>Sex</th>
<th>Age (yr)</th>
<th>Interferon</th>
<th>Duration (wk)</th>
<th>Total dose (MBq)</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CPH</td>
<td>Male</td>
<td>30</td>
<td>α-2b</td>
<td>14</td>
<td>480</td>
<td>NR</td>
</tr>
<tr>
<td>2</td>
<td>CPH</td>
<td>Female</td>
<td>39</td>
<td>α-2b</td>
<td>14</td>
<td>288</td>
<td>NR</td>
</tr>
<tr>
<td>3</td>
<td>CPH</td>
<td>Female</td>
<td>40</td>
<td>α-2b</td>
<td>24</td>
<td>210</td>
<td>NR</td>
</tr>
<tr>
<td>4</td>
<td>CPH</td>
<td>Male</td>
<td>44</td>
<td>α-2a</td>
<td>14</td>
<td>180</td>
<td>NR</td>
</tr>
<tr>
<td>5</td>
<td>CPH</td>
<td>Male</td>
<td>57</td>
<td>natural-α</td>
<td>24</td>
<td>390</td>
<td>R</td>
</tr>
<tr>
<td>6</td>
<td>CAH-2A</td>
<td>Male</td>
<td>53</td>
<td>natural-α</td>
<td>24</td>
<td>468</td>
<td>NR</td>
</tr>
<tr>
<td>7</td>
<td>CAH-2A</td>
<td>Female</td>
<td>21</td>
<td>natural-α</td>
<td>24</td>
<td>468</td>
<td>PR</td>
</tr>
<tr>
<td>8</td>
<td>CAH-2A</td>
<td>Female</td>
<td>26</td>
<td>α-2b</td>
<td>16</td>
<td>610</td>
<td>R</td>
</tr>
<tr>
<td>9</td>
<td>CAH-2A</td>
<td>Male</td>
<td>29</td>
<td>α-2a</td>
<td>24</td>
<td>792</td>
<td>R</td>
</tr>
<tr>
<td>10</td>
<td>CAH-2A</td>
<td>Male</td>
<td>54</td>
<td>α-2a</td>
<td>24</td>
<td>792</td>
<td>R</td>
</tr>
<tr>
<td>11</td>
<td>CAH-2A</td>
<td>Female</td>
<td>57</td>
<td>natural-α</td>
<td>16</td>
<td>324</td>
<td>R</td>
</tr>
<tr>
<td>12</td>
<td>CAH-2A</td>
<td>Female</td>
<td>48</td>
<td>natural-α</td>
<td>24</td>
<td>528</td>
<td>NR</td>
</tr>
<tr>
<td>13</td>
<td>CAH-2B</td>
<td>Female</td>
<td>54</td>
<td>α-2b</td>
<td>16</td>
<td>396</td>
<td>PR</td>
</tr>
<tr>
<td>14</td>
<td>CAH-2B</td>
<td>Female</td>
<td>58</td>
<td>natural-α</td>
<td>24</td>
<td>474</td>
<td>PR</td>
</tr>
<tr>
<td>15</td>
<td>CAH-2B</td>
<td>Female</td>
<td>62</td>
<td>α-2a</td>
<td>24</td>
<td>792</td>
<td>PR</td>
</tr>
<tr>
<td>16</td>
<td>CAH-2B</td>
<td>Female</td>
<td>67</td>
<td>α-2a</td>
<td>20</td>
<td>531</td>
<td>PR</td>
</tr>
<tr>
<td>17</td>
<td>CAH-2B</td>
<td>Male</td>
<td>51</td>
<td>α-2a</td>
<td>24</td>
<td>792</td>
<td>R</td>
</tr>
<tr>
<td>18</td>
<td>Cirrhosis</td>
<td>Male</td>
<td>42</td>
<td>natural-α</td>
<td>24</td>
<td>360</td>
<td>PR</td>
</tr>
<tr>
<td>19</td>
<td>Cirrhosis</td>
<td>Male</td>
<td>62</td>
<td>natural-α</td>
<td>24</td>
<td>552</td>
<td>PR</td>
</tr>
<tr>
<td>20</td>
<td>Cirrhosis</td>
<td>Male</td>
<td>52</td>
<td>α-2a</td>
<td>24</td>
<td>693</td>
<td>R</td>
</tr>
</tbody>
</table>

CPH = chronic persistent hepatitis; CAH = chronic aggressive hepatitis; R = responder; PR = partial responder; NR = nonresponder.
The differences among these groups were not significant.

The medians (tenth and 90th percentiles) of Li/B were 6.42 (5.77, 8.20) in CPH, 6.14 (4.00, 8.25) in CAH-2A, 5.11 (3.62, 7.50) in CAH-2B and 4.03 (2.62, 7.00) in cirrhosis of the liver (Fig. 2). The differences between the median Li/B of cirrhotic patients and the medians for patients with CPH, CAH-2A and CAH-2B were significant.

Changes in Lung and Liver Uptake of Gallium-67-Citrate with IFN Therapy

Figure 3 shows changes in Lu/B with IFN therapy. Lu/B increased in 16 of the 20 patients; it decreased in the other four patients. By the Wilcoxon rank-sum test, the overall decrease was significant (p < 0.01).

Figure 4 shows changes in Li/B with IFN therapy. Li/B increased in 11 of the 20 patients; it decreased in the other nine patients. The Wilcoxon rank-sum test showed no significant change.

DISCUSSION

Gallium-67-citrate couples to transferrin and lactoferrin in the blood and circulates through the body in the bloodstream to accumulate at inflammatory sites where it is taken into macrophages and neutrophils (21). We found significantly less accumulation in the liver in patients with cirrhosis than in patients with chronic hepatitis. This decrease is correlated with the decreased liver blood flow in cirrhosis, so Li/B could be an index of hepatic functional reserve. The counts per unit size of liver scans did not show enough improvement in hepatic functional reserve with IFN therapy to produce the increased after IFN therapy, but the improvement occurred a few years later and not during therapy.

After IFN therapy, the uptake of gallium-67-citrate was significantly higher than that before therapy (p = 0.0024). ● = responder; ○ = partial responder; ⊙ = nonresponder.

Alveolar inflammation is probably an early manifestation of idiopathic pulmonary fibrosis. Physiologic methods (coefficient of retraction and exercise tests of ∆P02/∆V02) can detect the progression of fibrosis, but it is difficult to evaluate alveolar inflammation in this disease without repeated lung biopsies. Gallium-67 scanning might be used to monitor the alveolitis of idiopathic pulmonary fibrosis because this isotope accumulates in regions of inflammation (23,24). Gallium-67-citrate is used to detect and characterize the inflammation of idiopathic pulmonary fibrosis because it binds to neutrophils (probably in lysosomes (25)), which are found in the parenchyma in this condition. Line et al. (26) reported that 67Ga scanning is useful not only for diagnosis but also for identification of the stage of the activity of this disease.

Drugs both cytotoxic (27) and not (28) can cause pulmonary disease. Cytotoxic drugs include anticancer drugs, and noncytotoxic drugs include antibacterial agents. IFN seems to have a different mechanism of action from either of these groups of drugs. We found a significant rise in 67Ga-citrate uptake into the lung after administration of IFN. This cytokine may trigger an excessive immune response, causing interstitial lung disease. (The unexpected decrease in uptake by four of the 20 patients might have occurred because of long-term fever and anorexia, both side effects of IFN therapy, causing decreased immune response.) Roth and Frank (29) reported the induction of acute interstitial pneumonia in cattle by a subcutaneous injection of bovine IFN-γ. Interstitial lung disease did not develop in the subjects of this study. IFN treatment was not started in two patients (with two of the four highest values in Fig. 1) because we noticed much accumulation of 67Ga-citrate in their lungs in the preliminary scanning and exercise tests of ∆P02/∆V02.
suggested interstitial lung disease. Probably these two patients were at special risk of developing interstitial lung disease. Ueda et al. (30) detected antibodies to hepatitis C virus in 19 of 66 patients (29%) with interstitial lung disease, the incidence being significantly higher than that in 9464 apparently healthy volunteers (346, or 4%, had such antibodies), and they suggested that hepatitis C virus might be implicated in this lung disease. If so, there being several patients before IFN therapy with unusually high Lu/B may be accounted for.

CONCLUSION

Changes in the accumulation of $^{67}$Ga-citrated were measured by calculation of the count per unit size in the ROI. Such changes could not have been inspected visually. This technique made numerical evaluation of the accumulation possible, so it seemed useful for the early diagnosis of interstitial lung disease caused by IFN and other drugs. Patients given IFN for treatment of liver disease had increased uptake of the radionuclide in their lungs, showing an increased immune response that might in some patients lead to interstitial lung disease.

REFERENCES


Detection of Postoperative Deep-Venous Thrombosis Using Technetium-99m-Labeled Tissue Plasminogen Activator

S. Patrick Butler, Tan Rahman, Samantha J. Boyd, Sharon L. Parkes and Richard J. Quinn

Department of Nuclear Medicine, St. George Hospital, Sydney, Australia

The current noninvasive methods of deep-venous thrombosis (DVT) detection in the asymptomatic patient are sufficiently inaccurate so as to preclude their routine use. This present study reports the accuracy of scintigraphic scanning with $^{99m}$Tc-t-PA in asymptomatic postoperative patients using contrast venography as the gold standard. Methods: Fifty-three consecutive postarthroplasty patients (30 THR, 23 TKR) (16 women, 37 men; mean age 71 yr; range 52–85 yr) underwent scintigraphic scanning with $^{99m}$Tc-t-PA and contrast venography, on the operated leg, in order to assess the accuracy of this new technique in these asymptomatic patients. Results: Eighty-four segments were of diagnostic quality on contrast venography. Of the 15 thrombosed segments, 14 had positive scans. In the 68 nonthrombosed segments, 63 had negative scans. Thus, scintigraphic scanning with $^{99m}$Tc-t-PA had a sensitivity of 93% and a specificity of 91%. Conclusion: This study demonstrated that scintigraphic scanning with modified $^{99m}$Tc-t-PA is accurate in the detection of DVT in patients undergoing total hip or total knee arthroplasty. Key Words: technetium-99m; recombinant tissue plasminogen activator; deep-venous thrombosis